Diabetes drug takes on statins in battle against fatty liver

NCT ID NCT07180745

Not yet recruiting Disease control Sponsor: Badr University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether empagliflozin (a diabetes drug) works better than statins for treating non-alcoholic fatty liver disease (NAFLD) and its more severe form, NASH. 400 obese, diabetic adults with NAFLD/NASH will take one of five drug combinations daily for 3 months. Researchers will measure liver fat and stiffness using a special ultrasound (FibroScan) and track side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin, Atorvastatin, Pioglitazone
What this could lead to: If successful, this could show that empagliflozin, alone or with statins, is a better option than statins alone for reducing liver fat and stiffness in people with NAFLD/NASH.
What could go wrong: This is a Phase 4 trial, so the drugs are already approved, but it's still early for this specific use. The 3-month treatment period is short, and results may not show lasting benefits or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH)

Contacts and locations

Locations

Teaching hospital of Beni Suef University

Banī Suwayf, 62727, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.